AstraZeneca PLC
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a AZNCF research report →
Companywww.astrazeneca.com
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. The company's marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; Seroquel IR/Seroquel XR for schizophrenia bipolar disease; Nexium, and Losec/Prilosec for gastroenterology; and Vaxzevria and Evusheld for covid-19.
- CEO
- Pascal Claude Roland Soriot
- IPO
- 2009
- Employees
- 94,300
- HQ
- Cambridge, GB
Price Chart
Valuation
- Market Cap
- $294.40B
- P/E
- 27.78
- P/S
- 4.78
- P/B
- 6.14
- EV/EBITDA
- 15.44
- Div Yield
- 1.69%
Profitability
- Gross Margin
- 79.71%
- Op Margin
- 23.53%
- Net Margin
- 17.19%
- ROE
- 22.41%
- ROIC
- 12.88%
Growth & Income
- Revenue
- $58.74B · 8.63%
- Net Income
- $10.22B · 45.34%
- EPS
- $6.60 · 45.37%
- Op Income
- $13.74B
- FCF YoY
- 19.18%
Performance & Tape
- 52W High
- $209.48
- 52W Low
- $122.26
- 50D MA
- $183.86
- 200D MA
- $161.39
- Beta
- 0.19
- Avg Volume
- 161.84K
Get TickerSpark's AI analysis on AZNCF
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our AZNCF Coverage
We haven't published any research on AZNCF yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate AZNCF Report →